Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Nectar Lifesciences Ltd (NECLIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532649 NSE: NECLIFE Pharmaceuticals & Drugs | Small Cap | Nectar Lifesciences Share Price

₹11.50 -0.45 (-3.77%)

As on 11-Sep'26 16:59

Nectar Lifesciences Ltd (NECLIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532649 NSE: NECLIFE Pharmaceuticals & Drugs | Small Cap | Nectar Lifesciences Share Price

₹11.50 -0.45 (-3.77%)

As on 11-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹223 Cr.
Current Price
₹11.5
52-Week Low / High
₹9 / 22
TTM EPS
₹-12.6
TTM Sales
₹5 Cr.
Book Value per Share
₹29.2
P/E Ratio
0.00
Lower than its 3-year historical median
Industry PE
54.2
Price to Book (P/B)
0.39
Lower than its 5-year historical median
Price to Sales (P/S)
44.58
Higher than its 5-year historical median
EV/EBITDA
-1.45
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-7.46%
Underperforms industry median
Return on Capital Employed (ROCE)
-4.75%
Underperforms industry median
Return on Assets (ROA)
-4.80%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-8292.86%
Asset Quality
Promoter Holding
51.84%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹547 Cr.
Equity
₹19.4 Cr.
Face Value
₹1
All Time Low / High
₹7.20 / 60.90

Nectar Lifesciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Somewhat Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Nectar Lifesciences Ltd a good quality company?
Nectar Lifesciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Nectar Lifesciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Nectar Lifesciences Ltd vs industry peers?
Nectar Lifesciences Ltd revenue CAGR is -100.00%, compared to the industry median CAGR of 0.00%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Nectar Lifesciences Ltd?
Promoters hold 51.84% of the Nectar Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Nectar Lifesciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -11.6% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nectar Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ9.7%9.1%10.3%8.2%1.4%5.8%2.6%6.7%0.6%-4.8%-
Value Creation
Index ⓘ		-0.3-0.4-0.3-0.4-0.9-0.6-0.8-0.5-1.0-1.3-

Growth Parameters ⓘ
Sales ⓘ1,6431,8762,7852,3631,5421,6681,5241,684005
Sales YoY Gr.-14.1%48.5%-15.2%-34.8%8.2%-8.7%10.5%-100%NA-
Adj EPS ⓘ2.42.32.11.3-2.50.8-2.6-0.1-0.2-1.10.9
YoY Gr.--3.7%-9%-37.3%-285.7%NA-406%NANANA-
BVPS (₹) ⓘ44.947.249.350.647.348.547.547.742.63029.3
Adj Net
Profit ⓘ		54.352.247.529.9-55.418.7-57.7-2-5.3-21.717
Cash Flow from Ops. ⓘ19965.123928621.395133225169-417-
Debt/CF from Ops. ⓘ4.414.73.82.742.49.15.72.83.40-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ-100%-100%-100%NA
Adj EPS ⓘ-191.8%NANANA
BVPSⓘ-4.4%-8.7%-14.2%-29.7%
Share Price -11.6% -17.3% -23.4% -27%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		5.55.14.42.7-51.7-5.4-0.2-0.5-2.82.9
Op. Profit
Mgn % ⓘ		13.612.69.59.26.69.53.6900-394.9
Net Profit
Mgn % ⓘ		3.32.81.71.3-3.61.1-3.8-0.100333.5
Debt to
Equity ⓘ		0.90.90.80.70.90.80.70.60.60-
Working Cap
Days ⓘ		324292206240330288310272001,166
Cash Conv.
Cycle ⓘ		15313310411513210812610900-2,043

Valuation of Nectar Lifesciences - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.00100.0099.6099.6099.6098.770.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales1,6441,8762,7832,3661,5431,6691,5241,68400
Operating Expenses ⓘ + 1,4191,6402,5192,1471,4421,5101,4711,533061
Manufacturing Costs12914515414012914717318600
Material Costs1,1541,3672,2181,8591,1571,2231,1591,20200
Employee Cost 767577787172758201
Other Costs ⓘ 6154717085686463060
Operating Profit ⓘ 22423626422010115953152-0-61
Operating Profit Margin (%) 13.7%12.6%9.5%9.3%6.6%9.5%3.5%9.0%--
Other Income ⓘ + 23664111153171011
Exceptional Items ⓘ 0000-2500000
Interest ⓘ 117115148126112798990937
Depreciation ⓘ 626463616057596110
Profit Before Tax ⓘ 67635937-8534-42181-88
Tax ⓘ 1210116-129-18130-31
Profit After Tax 55524832-7325-2451-57
PAT Margin (%) 3.4%2.8%1.7%1.3%-4.8%1.5%-1.6%0.3%--
Adjusted EPS (₹)2.52.42.11.4-3.31.1-1.10.2-5.1-15.1
Dividend Payout Ratio (%)2%2.10%2.30%3.50%0%0%0%0%0%0%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 1,0071,0591,1051,1361,0621,0881,0651,069956582
Share Capital ⓘ 22222222222222222219
Reserves ⓘ 9841,0361,0831,1141,0401,0651,0421,047934563
Debt +7948548027418407946855535000
Long Term Debt164220166121128291226140600
Short Term Debt6306346366207125034594124400
Minority Interest0000000000
Trade Payables5285394845273423773194204380
Others Liabilities ⓘ 25227231522913113010014298-185
Total Liabilities ⓘ 2,5812,7242,7052,6332,3762,3882,1692,1841,992397

Fixed Assets

Net Fixed Assets ⓘ +881852825785772723662643633105
Gross Block1,3641,4561,4901,5091,5561,5631,5581,5991,652107
Accumulated Depreciation4826046667247848408969571,0192
CWIP ⓘ 10210010011599857866570
Investments ⓘ 11101111113
Inventories8558599189785886606737096900
Trade Receivables5006125593963754472803793450
Cash Equivalents 13921212618182019112
Others Assets ⓘ 229290282338516455459366247167
Total Assets ⓘ 2,5812,7242,7052,6332,3762,3882,1692,1841,992397
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 199652392852195134225169-349
PBT ⓘ 67635937-8534-4218-162-789
Adjustment ⓘ 15917620718615012598138139234
Changes in Working Capital ⓘ -20-161-1370-41-657869192206
Tax Paid ⓘ -7-13-14-9-400000
Cash Flow From Investing Activity ⓘ + -18-29-26-33-291752-17-421,208
Capex -25-33-36-36-311550-29-448
Net Investments 0-000-00000-65
Others ⓘ 731033221221,265
Cash Flow From Financing Activity ⓘ + -204-40-201-25211-119-186-205-128-767
Net Proceeds from Shares ⓘ 0000000000
Net Proceeds from Borrowing ⓘ -8773-53-10832166-62-72-82-209
Interest Paid ⓘ -117-115-148-126-112-79-79-87-75-36
Dividend Paid ⓘ -3-1-1-1-100000
Others ⓘ 342-1692-206-44-4728-521
Net Cash Flow ⓘ -23-412-04-8-02-193
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)5.645.064.42.84-6.672.33-2.250.470.07-7.46
ROCE (%)9.739.1310.298.321.415.772.496.120.59-4.75
Asset Turnover Ratio0.680.791.150.990.70.810.770.8800
PAT to CFO Conversion(x)3.621.254.988.91N/A3.8N/A45169N/A
Working Capital Days
Receivable Days103.7096.9068.6065.9079.8077.9075.9062.4000
Inventory Days177149.50104.20130.90162118.30139.20130.9000
Payable Days162142.5084.2099.30137.10107.30109.50112.1000

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Nectar Lifesciences Ltd FAQs

The current trading price of Nectar Lifesciences on 11-Sep-2026 16:59 is ₹11.50.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Nectar Lifesciences stood at ₹223.4 Cr

The latest P/E ratio of Nectar Lifesciences as of 10-Sep-2026 is 13.43.

The latest P/B ratio of Nectar Lifesciences as of 10-Sep-2026 is 0.39.

The 52-week high of Nectar Lifesciences is ₹22.49 and the 52-week low is ₹9.20.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹5.01 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.

The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Nectar Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Nectar Lifesciences Ltd

Nectar Lifesciences (Nectar) is a research-driven, leading manufacturer of Active Pharmaceutical Ingredients (API), intermediates as well as Finished dosage forms offering largest segment of anti-infectives namely Cephalosporins. Nectar has proven to be a reliable CMO (Contract Manufacturing Organization) to global pharma innovators. Nectar has leading global capacities in Cephalosporin antibiotics such as Cefixime, Cefuroxime Axetil Amorphous, Cefuroxime Axetil Crystalline, Cefotaxime Sodium, Ceftriaxone Sodium. 

The company is the world’s leading producer of Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil and Sterile APIs. All of the company’s plants can be converted to multi-purpose plants based on product basket requirement.

Business area of the company

Nectar is a global pharmaceutical company specializing in Cephalosporins.

Products

Oral Cephalosporins:

  • Cefixime
  • Cefurozime Axetil Crystalline
  • Cefuroxime Axetil Amorphous
  • Cedpodoxime Proxetil
  • Cefprozil
  • Cefdinir

Sterile Cephalosporins:

  • Cefotaxime Sodium
  • Ceftriaxone Sodium
  • Cefuroxime Sodium
  • Cefazolin Sodium
  • Ceftazidime pentahydrate
  • Cefepime +Arginine

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now